Viking Therapeutics, Inc. (VKTX) Rises Higher Than Market: Key Facts
Viking Therapeutics, Inc. (VKTX) reached $31.29 at the closing of the latest trading day, reflecting a +2.93% change compared to its last close.
Viking Therapeutics, Inc. (VKTX) Rises Higher Than Market: Key Facts
Viking Therapeutics, Inc. (VKTX) closed at $28.19 in the latest trading session, marking a +1.7% move from the prior day.
Is Viking Therapeutics (VKTX) a Buy as Wall Street Analysts Look Optimistic?
Investors often turn to recommendations made by Wall Street analysts before making a Buy, Sell, or Hold decision about a stock. While media reports about rating changes by these brokerage-firm employed (or sell-side) analysts often affect a stock's price, do they really matter?
Viking Therapeutics, Inc. (VKTX) Stock Drops Despite Market Gains: Important Facts to Note
The latest trading day saw Viking Therapeutics, Inc. (VKTX) settling at $26.52, representing a -5.86% change from its previous close.
VKTX Initiates Phase 3 Study on Obesity Candidate VK2735
Viking begins phase III VANQUISH program for VK2735, targeting weight loss in obese adults with or without type II diabetes.
Brokers Suggest Investing in Viking Therapeutics (VKTX): Read This Before Placing a Bet
Investors often turn to recommendations made by Wall Street analysts before making a Buy, Sell, or Hold decision about a stock. While media reports about rating changes by these brokerage-firm employed (or sell-side) analysts often affect a stock's price, do they really matter?
Viking Therapeutics, Inc. (VKTX) Stock Drops Despite Market Gains: Important Facts to Note
The latest trading day saw Viking Therapeutics, Inc. (VKTX) settling at $28.59, representing a -1.26% change from its previous close.
Is It Worth Investing in Viking Therapeutics (VKTX) Based on Wall Street's Bullish Views?
The recommendations of Wall Street analysts are often relied on by investors when deciding whether to buy, sell, or hold a stock. Media reports about these brokerage-firm-employed (or sell-side) analysts changing their ratings often affect a stock's price.
Viking Therapeutics: Buy It For The Future And Ignore The Noise
VKTX remains a speculative, high-risk/reward play, with its future hinging on successful Phase III trial results for its obesity drug pipeline. The company's strong cash position and recent manufacturing partnerships support its path toward commercialization, despite expected negative free cash flow through FY2028. VKTX's diversified pipeline, including NAFLD and rare disease prospects, provides some downside protection as it awaits pivotal clinical milestones.
Viking Therapeutics: Weight-Loss Story Remains Intact
Viking Therapeutics remains a promising weight-loss drug biotech due to the enrollment of new promising trials. The weight-loss sector's momentum has faded some, but Eli Lilly and Novo Nordisk have still generated substantial value for shareholders. Viking Therapeutics has upcoming catalysts, including late-July Phase 2 oral data and Phase 3 injectable trial enrollment, potentially driving significant upside in the stock.
Viking Therapeutics: A High Potential Biotech Play With Manageable Risks
Viking targets massive, validated markets with GLP-1/GIP and THR-β agonists, offering injectable and oral alternatives with promising Phase 2/3 results. Positioned as a second-line, tolerable, patient-friendly treatment in an established space with significant addressable market size. Compared to some other binary bets in big pharma, Viking offers leaner operations, lower complexity, faster trial execution, and less execution risk.
Viking Therapeutics: Near-Term Catalysts And Competitor Readouts
VKTX's VENTURE-Oral study of VK2735 has completed enrollment, with a readout set for H2'25. The company's phase 3 program on subcutaneous VK2735 is getting underway, although given it will contain thousands of patients, a readout isn't a near-term prospect. VKTX will evaluate once-monthly maintenance dosing of VK2735 in 2025, which could allow it to confirm it can compete with the likes of agents from AMGN and MTSR.
